Pharsight

Drugs that contain Carbidopa; Levodopa

1. Dhivy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11819485 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

US11033521 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

US11439613 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

Market Authorisation Date: 12 November, 2021

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease;...

Dosage: TABLET;ORAL

More Information on Dosage

DHIVY family patents

Family Patents

2. Rytary patents expiration

RYTARY's oppositions filed in EPO
Can you believe RYTARY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7094427 IMPAX LABS INC Combination immediate release controlled release levodopa/carbidopa dosage forms
May, 2022

(1 year, 9 months ago)

US9089607 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US8377474 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US8454998 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US8557283 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9901640 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9533046 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9089608 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9463246 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

Market Authorisation Date: 07 January, 2015

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Method of providing a therapeutically effecti...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of RYTARY before it's drug patent expiration?
More Information on Dosage

RYTARY family patents

Family Patents